521 Global Pharma C-Level Executives Confirmed for BIOCHINA2026

BIOCHINA2026, scheduled to take place from March 12 to 14 in Suzhou, has confirmed the participation of 521 C-level executives from leading global and Chinese biopharmaceutical companies. The list of attendees includes senior leaders from multinational corporations driving research and development and strategic partnerships, innovative pharmaceutical CEOs advancing pipeline development, CDMO executives shaping drug development and manufacturing, as well as founders of pioneering biotech companies specializing in gene and cell therapies.

As one of the premier biopharma events in Asia, BIOCHINA2026 provides an unparalleled platform for high-level networking, strategic collaboration, and knowledge exchange. The conference will bring together decision-makers, industry innovators, and investors to discuss emerging trends, investment opportunities, and the latest scientific and technological breakthroughs in the pharmaceutical and biotechnology sectors.

Attendees will have the opportunity to engage in in-depth discussions on topics ranging from novel drug development and advanced manufacturing solutions to global regulatory strategies and cross-border partnerships. By facilitating direct interaction between Chinese and international leaders, BIOCHINA2026 aims to strengthen collaboration across the global biopharma ecosystem and accelerate the translation of innovative therapies from research to market.

The event also highlights the increasing role of China in the global pharmaceutical landscape. With a growing pipeline of innovative drugs and expanding manufacturing capabilities, Chinese biopharma companies are becoming key players in international partnerships, licensing deals, and technology collaborations. BIOCHINA2026 serves as a strategic meeting point where global executives can explore opportunities for co-development, licensing, and investment.

For the full list of confirmed C-level executives, please visit: BIOCHINA2026 C-Level List